
Dr Yu on Factors Influencing PARP Inhibitor Selection in mCRPC
Evan Ya-Wen Yu, MD, discusses the PARP inhibitors that are available for the treatment of patients with mCRPC.
“I don’t envision a world where [talazoparib plus enzalutamide] is approved for all-comers, but I do believe the current [FDA] approval will get a reasonable amount of utility because, unlike the other combinations, it had an overall survival benefit and looking at the gene-by-gene breakdown, there are promising results for [patients with] some gene mutations that some of the other PARP inhibitors do not have.”
Evan Ya-Wen Yu, MD, section head, medical oncology, professor, Clinical Research Division, Fred Hutchinson Cancer Center, discussed the PARP inhibitors that are available for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and the differences that he considers when selecting between them.
First, investigators must decide whether they are using monotherapy or a combination approach, Yu began. FDA-approved monotherapies include rucaparib (Rubraca) and olaparib (Lynparza).
A unique study leading in mCRPC was the phase 3 TALAPRO-2 trial (NCT03395197), which supported the
Additionally, at the
Related to this article






